+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

Over the past several years, cancer immunotherapy has made extraordinary progress both conceptually and in clinical practice. The recent FDA approval of drugs in this area has paved the way for many upcoming independent and combination therapies in the immuno-oncology segment.

A variety of strategies are continuing to evolve in the laboratory and in the clinic, including cancer vaccines, T cells, and immune checkpoint blockade. Despite their promise, much more research is needed to understand how and why certain cancers fail to respond to immunotherapy and to predict which therapeutic strategies, or combinations thereof, are most appropriate for each patient.

The Cancer Immunotherapy Congress held on 19 - 20 May 2016 in Boston, USA presented these ongoing challenges along with some recent technological advances.

Key sessions:

• Cellular Immunotherapy
• Predictive Biomarkers for response
• Combinational Therapy and Toxicity
• New Immunotherapy Targets
• Pre-clinical & Translational
• Moving Beyond Current Vaccines

Key Speakers:

  • James B. Trager
    Vice President, Research
    Dendreon Pharmaceuticals, Inc,
    Seattle, USA
  • Jeffrey H. Hanke
    Executive Vice President, Research and Development, and CSO TESARO,
    Massachusetts, USA
  • Dr. Scott Cameron
    Senior Director and Clinical Program Leader
    Novartis Oncology Translational Research,
    Boston, USA
  • Kuldeep Neote
    Senior Director, New Ventures
    Johnson & Johnson Innovation, 
    California, USA
  • James Gulley
    Chief, Genitourinary Malignancies Branch
    Director, Medical Oncology Service, Center for Cancer Research
    NCI, NIH, Washington, USA
  • Michael Briskin 
    Vice President, Discovery research
    Jounce Therapeutics,
    Cambridge, USA

conference Registration Form



Academic Delegate$499
Industry Delegate $699
Solution Provider Delegate$999
University & Research Institutes (Early Bird) - 30th June 2017$399 (Till 31st March)


Key sessions:

  • Cellular Immunotherapies
  • Potential Predictive Biomarkers for response?
  • Combinational Therapy & Toxicity

Who Should Attend ?

Who attended?

Scientists, academicians and professionals from 
• Pharmaceutical and Bio-pharmaceutical companies
• Bio-technology companies
• Research institutes

Working in:

• Drug Discovery
• Drug Screening
• Oncology R&D
• Cancer Immunotherapy/ Immuno-oncology
• Immunotherapy R&D

Why they attended:

• 30+ experts from academia and industry present case studies on cancer immunotherapy drugs
• Focused discussions on challenges on upcoming therapies like combination therapies
• Facilitated networking sessions to ensure quality interactions
• One on one query handling by top Immuno-oncology experts
• Intensive brainstorming on effective drug development and FDA approval


  • Dr. James B. Trager

    Vice President, Research Dendreon Pharmaceuticals, Inc, Seattle, USA
  • Dr. Jeffrey H. Hanke

    Executive Vice President - Research And Development & CSO TESARO, Massachusetts, USA
  • Dr. Michael Briskin

    Biotechnology Consultant, USA
  • Dr. Kuldeep Neote

    Senior Director, New Ventures Johnson & Johnson Innovation, California, USA
  • Dr. Scott Cameron

    Senior Director, Oncology Research Physician, Translational Clinical Oncology, Novartis, Boston
  • Dr. Elaine Pinheiro

    Principal Scientist & Pre - Clinical Lead Pembrolizumab (Keytruda) Program, IMR Early Discovery, Merck Research Laboratories, Boston
  • Dr. James Gulley

    M.D., Ph.D., F.A.C.P. Chief, Genitourinary Malignancies Branch Director, Medical Oncology Service Center for Cancer Research, NCI, NIH, Washington, USA
  • Dr. Aaron Foster

    Senior Director Cellular Biology & Immunology, Bellicum Pharmaceuticals, Texas, USA
  • Dr. Joshua Brody

    Director, Lymphoma Immunotherapy Program, Mount Sinai School Of Medicine, New York, USA
  • Dr. Jianda Yuan

    Director of Translational Immuno-Oncology Research, Merck
  • Dr. Marcela Maus

    Director of Cellular Immunotherapy Cancer Center Massachusetts General Hospital, Massachusetts, USA
  • Dr. Hye-Jung Kim

    Senior scientist Dana-Farber Cancer Institute, Boston, USA
  • Dr. Omar Eton

    Associate Professor of Medicine Boston Medical Centre, Boston, USA
  • Dr. Ryan Sullivan

    Instructor, Medicine, Harvard Medical School, Assistant in Medicine, MGH Cancer Center Massachusetts General Hospital, Massachusetts, USA
  • Dr. Jennifer Michaelson

    Director of Pharmacology and Program, Jounce Therapeutics
  • Dr. Rita Shaknovich

    M.D., Ph.D. Medical Director and Vice President of Hematopathology
  • Dr. Eunice Lee

    Branch Chief, Division of Molecular Genetics and Pathology of the Office of In Vitro Diagnostics and Radiological Health CDRH, FDA, Maryland
  • Dr. Lata Jayaraman

    Director, Pharmacology and Translational Research Cerulean Pharma, Massachusetts
  • Dr. Jane Houldsworth

    Vice President of Research and Development Cancer Genetics Inc., New Jersey
  • Dr. Ellen Puré

    Grace Lansing Lambert Professor of Biomedical Science Chair, Department of Biomedical Sciences School of Veterinary Medicine University of Pennsylvania
  • Dr.Souhil Zaim

    Chief Medical Officer, Median Technologies, San Fransisco
  • Dr. Carol O'Hear

    Asst Medical Director, Cancer Immunotherapy, Genentech, San Fransisco
  • Dr. Jonathan Pachter

    CSO, Verastem, Inc, Massachusetts
  • Dr. Ashwani Sood

    Assistant Member, Department of Immunology Roswell Park Cancer Institute, New York
  • Dr. John Burke

    Co-Founder, President, and CEO, Applied BioMath, Massachusetts
  • Dr. Jennifer Wargo

    Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer, Texas
  • Dr. Michail V. Sitkovsky

    E.W. Black Chair and Professor of Immunophysiology and Pharmaceutical Biotechnology Presidential Scholar, Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Institutes of Medicine, Boston


Platinum Sponsor

Cancer Genetics Inc.Cancer Genetics Inc. 
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. We also offer a comprehensive range of oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.


Silver Sponsor

Median TechnologiesMedian Technologies 

MEDIAN Technologies is a full service imaging contract research organization. We provide medical imaging services for phase I–III oncology trials, and science and services for image interpretation and management. MEDIAN Technologies enables quantitative analysis of images and helps standardize image interpretation for accurate measurement of tumor burden in cancer patients. We support biopharma sponsors in their oncology trials worldwide and actively work with clinical sites located in Asia, Europe, North and South America, and Australia.


Applied BioMathApplied BioMath

Applied BioMath, the industry-leader in applying mechanistic modeling to drug development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.    Applied BioMath leverages biology, proprietary technology, high-performance computing, and industry experience to help better understand a candidate, its best-in-class (BIC) parameters, competitive advantages, and best path forward.   Our approach shortens project timelines, lowers cost, increases the likelihood of a BIC drug, and when validated in the clinic, is 10x more accurate than traditional methodologies.


NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community.

 NeoGenomics offers the complete spectrum of diagnostic services in immunohistochemistry, FISH, flow cytometry, cytogenetics, and molecular testing through our nationwide network of laboratories. We are dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients.

Advanced Cell Diagnostics Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. ACD’s products and services are based on its proprietary RNAscope® Technology capable of detecting RNA biomarkers in situ at single molecule sensitivity. This unique technology delivers quantitative, sensitive and specific molecular detection of RNA biomarkers with morphological context in a single assay.

Myriad RBMMyriad RBM

Myriad RBM, Inc. is a leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology. This platform provides researchers with reproducible and quantitative data for hundreds of proteins in a cost-effective manner.  All services are performed in our CLIA certified laboratory.



Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

Posters should be presented as A0 or US equivalent, size E (841mm x 1189mm or 34 x 44 inches respectively) in portrait orientation.

For further details and requirements please contact:

Ajay Nimbalkar
Email: ajay.nimbalkar@mnmconferences.com
Tel:+91 20 6708 0299

Posters Submission Form



Four Points Sheraton Wakefield Boston
1 Audubon Road

For directions, click here

Our block of rooms at the Four Points Sheraton Wakefield Boston has now expired. You may still be able to book accommodation at the Four Points Sheraton Wakefield Boston by visiting their website directly - http://www.starwoodhotels.com/fourpoints/property/overview/index.html?propertyID=232/ Alternatively, you can see a list of nearby hotels by clicking here.

(Please note that we do not authorise any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than me regarding your accommodation requirements for this event, please let me know immediately)